The study will examine multiple myeloma to understand how race affects diagnosis, treatment patterns and patient outcomes, according to a June 23 news release.
Multiple myeloma disproportionately affects Black Americans. It is the second most common hematologic malignancy, with 34,920 new cases and 12,410 deaths expected in 2021. Black Americans are diagnosed at rates two to three times higher than the general population, with Black patient deaths at a higher rate as well.
Benjamin Derman, MD, oncology professor at University of Chicago Medicine, said: “Black Americans are grossly underrepresented in clinical trials, and more data is needed to evaluate the best treatments for this population. It is critical that we understand optimal treatment pathways and risk prognostication in Black populations.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.